RxDoctor Payments Data

Scott Steven, DO

Endocrinology, Diabetes & Metabolism · Cherry Hill, NJNPI 1336552397

Payments from drug & device makers

$8,888in general payments, 2019–2025

Across 28 payments — averaging $317.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • C. R. Bard, Inc. & Subsidiaries$7K
  • Novo Nordisk$568
  • AbbVie$496
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$125
  • Dova Pharmaceuticals$125
  • Gilead$124
  • plus $493 from 8 others

What the payments were for

  • Consulting fees$6,20070%
  • Travel & lodging$7589%
  • Food & beverage$1,93022%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,888 in reported general payments places this provider in the 75th percentile of 367 endocrinology, diabetes & metabolism providers in New Jersey.

See all endocrinology, diabetes & metabolism providers in New Jersey

Medicare billing

Part B allowed, 2024
$93,447
Medicare patients
395
Services billed
765

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide196$367,923
TrulicityDulaglutide95$171,080
JardianceEmpagliflozin129$153,777
JanuviaSitagliptin Phosphate133$142,257
Bydureon BciseExenatide Microspheres45$65,020
Lantus SolostarInsulin Glargine,hum.Rec.Anlog356$56,510
Humulin R U-500 KwikpenInsulin Regular, Human38$53,906
Victoza 3-PakLiraglutide36$53,187
Fiasp FlextouchInsulin Aspart (Niacinamide)34$52,846
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog103$52,679
Tresiba Flextouch U-100Insulin Degludec49$51,442
MounjaroTirzepatide34$50,982
Humalog Kwikpen U-100Insulin Lispro104$40,091
Novolog FlexpenInsulin Aspart104$37,677
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog31$32,871

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$568$367,923196 claims
Johnson & JohnsonInvokana$110$14,53613 claims
AbbVieSynthroid$496$6,28476 claims
Sanofi-aventis U.S. LLCLantus$18$2,57013 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 367 endocrinology, diabetes & metabolism providers in New Jersey.

Other endocrinology, diabetes & metabolism in Cherry Hill

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →